Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study

Published:2023-05 Issue: Volume:211 Page:107172
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Van Zyl-Smit Richard N.^ORCID,Kerstjens Huib AM.^ORCID,Maspero Jorge F.,Kostikas Konstantinos^ORCID,Hosoe Motoi,Tanase Ana- Maria,D'Andrea Peter,Mezzi Karen,Brittain Dominic^ORCID,Lawrence David,Chapman Kenneth R.^ORCID

Funder

Novartis

Novartis Pharma AG

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. Global Strategy for Asthma Management and Prevention,2022

2. Factors associated with persistent airflow limitation in severe asthma;ten Brinke;Am. J. Respir. Crit. Care Med.,2001

3. Asthma, airflow limitation and mortality risk in the general population;Huang;Eur. Respir. J.,2015

4. Risk factors associated with irreversible airflow limitation in asthma;ten Brinke;Curr. Opin. Allergy Clin. Immunol.,2008

5. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study;Kole;Lancet Respir. Med.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP